Global Viral Vaccine

Viral Vaccine Comprehensive Study by Type (Inactivated Vaccine, Live-attenuated Vaccine, Viral vector Vaccine, Nucleic acid Vaccine, Others), Disease (Pneumococcal Disease, DTP, Influenza, HPV, Meningococcal Disease, Polio, Rotavirus, Hepatitis, MMR, Varicella, Herpes zoster, Other), Side Effects (Pain, swelling, or redness, Mild fever, Chills, Feeling tired, Headache, Muscle and joint aches), Patients (Pediatric Patients, Adult Patients) Players and Region - Global Market Outlook to 2028

Viral Vaccine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Viral Vaccine Market Overview:
Viral Vaccines, regularly recognized as immunizations, are injections of a disease's weakened shape into a person's physique to reason the physique to produce antibodies or immunity towards the disease. A variety of illnesses with big mortality rates, such as polio and smallpox, have been eradicated thanks to high quality immunisation. Vaccinations are used in a range of regional disease-prevention programmes due to the fact that they serve such an essential position in preserving people's long-term fitness in exclusive countries. The demand for immunizations has risen in latest years as the incidence of viral and bacterial infectious ailments has increased. Vaccinations are specially given to humans of all a long time to raise their immune structures and supply safety towards a variety of infectious illnesses at some stage in their lives. Vaccines assist to fortify your immune device and shield you from dangerous, life-threatening diseases.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Introduction to new vaccines and technology

Market Growth Drivers:
Rising number of companies to enhance R&D and Growing prevalence infectious diseases

Challenges:
Stringent government regulations for product approval of new product introduction and Vaccine manufacturer needs to establish good relationships with numerous third parties for their portfolio of vaccines

Restraints:
High cost associated with vaccine

Opportunities:
Increase in investment toward development of new vaccines

Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are GlaxoSmithKline plc. (United Kingdom), Pfizer, Inc. (United States), Merck & Co., Inc. (United States), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (United States), Johnson & Johnson (United States), Serum Institute of India (India), AstraZeneca (United Kingdom) and Bavarian Nordic (Denmark). Additionally, following companies can also be profiled that are part of our coverage like Mitsubishi Tanabe Pharma Corporation (Japan) and Daiichi Sankyo Company, Limited (Japan). Analyst at AMA Research see United States Players to retain maximum share of Global Viral Vaccine market by 2028. Considering Market by Disease, the sub-segment i.e. Pneumococcal Disease will boost the Viral Vaccine market. Considering Market by Side Effects, the sub-segment i.e. Pain, swelling, or redness will boost the Viral Vaccine market. Considering Market by Patients, the sub-segment i.e. Pediatric Patients will boost the Viral Vaccine market.

In 2020, Pfizer and the German company BioNTech made history by announcing that their coronavirus vaccine had an efficacy rate of over 90 percent, far surpassing expectations. It was the first time anyone had found such evidence. Just over a month later, on Dec. 11, the Food and Drug Administration granted the vaccine, known as Comirnaty, the first emergency use authorization ever given by the United States to a coronavirus vaccine.

What Can be Explored with the Viral Vaccine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Viral Vaccine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Viral Vaccine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Viral Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Viral Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Viral Vaccine Manufacturers, Viral Vaccine Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Inactivated Vaccine
  • Live-attenuated Vaccine
  • Viral vector Vaccine
  • Nucleic acid Vaccine
  • Others
By Disease
  • Pneumococcal Disease
  • DTP
  • Influenza
  • HPV
  • Meningococcal Disease
  • Polio
  • Rotavirus
  • Hepatitis
  • MMR
  • Varicella
  • Herpes zoster
  • Other

By Side Effects
  • Pain, swelling, or redness
  • Mild fever
  • Chills
  • Feeling tired
  • Headache
  • Muscle and joint aches

By Patients
  • Pediatric Patients
  • Adult Patients

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising number of companies to enhance R&D
      • 3.2.2. Growing prevalence infectious diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent government regulations for product approval of new product introduction
      • 3.3.2. Vaccine manufacturer needs to establish good relationships with numerous third parties for their portfolio of vaccines
    • 3.4. Market Trends
      • 3.4.1. Introduction to new vaccines and technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Viral Vaccine, by Type, Disease, Side Effects, Patients and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Viral Vaccine (Value)
      • 5.2.1. Global Viral Vaccine by: Type (Value)
        • 5.2.1.1. Inactivated Vaccine
        • 5.2.1.2. Live-attenuated Vaccine
        • 5.2.1.3. Viral vector Vaccine
        • 5.2.1.4. Nucleic acid Vaccine
        • 5.2.1.5. Others
      • 5.2.2. Global Viral Vaccine by: Disease (Value)
        • 5.2.2.1. Pneumococcal Disease
        • 5.2.2.2. DTP
        • 5.2.2.3. Influenza
        • 5.2.2.4. HPV
        • 5.2.2.5. Meningococcal Disease
        • 5.2.2.6. Polio
        • 5.2.2.7. Rotavirus
        • 5.2.2.8. Hepatitis
        • 5.2.2.9. MMR
        • 5.2.2.10. Varicella
        • 5.2.2.11. Herpes zoster
        • 5.2.2.12. Other
      • 5.2.3. Global Viral Vaccine by: Side Effects (Value)
        • 5.2.3.1. Pain, swelling, or redness
        • 5.2.3.2. Mild fever
        • 5.2.3.3. Chills
        • 5.2.3.4. Feeling tired
        • 5.2.3.5. Headache
        • 5.2.3.6. Muscle and joint aches
      • 5.2.4. Global Viral Vaccine by: Patients (Value)
        • 5.2.4.1. Pediatric Patients
        • 5.2.4.2. Adult Patients
      • 5.2.5. Global Viral Vaccine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Viral Vaccine (Volume)
      • 5.3.1. Global Viral Vaccine by: Type (Volume)
        • 5.3.1.1. Inactivated Vaccine
        • 5.3.1.2. Live-attenuated Vaccine
        • 5.3.1.3. Viral vector Vaccine
        • 5.3.1.4. Nucleic acid Vaccine
        • 5.3.1.5. Others
      • 5.3.2. Global Viral Vaccine by: Disease (Volume)
        • 5.3.2.1. Pneumococcal Disease
        • 5.3.2.2. DTP
        • 5.3.2.3. Influenza
        • 5.3.2.4. HPV
        • 5.3.2.5. Meningococcal Disease
        • 5.3.2.6. Polio
        • 5.3.2.7. Rotavirus
        • 5.3.2.8. Hepatitis
        • 5.3.2.9. MMR
        • 5.3.2.10. Varicella
        • 5.3.2.11. Herpes zoster
        • 5.3.2.12. Other
      • 5.3.3. Global Viral Vaccine by: Side Effects (Volume)
        • 5.3.3.1. Pain, swelling, or redness
        • 5.3.3.2. Mild fever
        • 5.3.3.3. Chills
        • 5.3.3.4. Feeling tired
        • 5.3.3.5. Headache
        • 5.3.3.6. Muscle and joint aches
      • 5.3.4. Global Viral Vaccine by: Patients (Volume)
        • 5.3.4.1. Pediatric Patients
        • 5.3.4.2. Adult Patients
      • 5.3.5. Global Viral Vaccine Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Viral Vaccine (Price)
      • 5.4.1. Global Viral Vaccine by: Type (Price)
  • 6. Viral Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi Pasteur SA (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CSL Limited (Australia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Emergent BioSolutions, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Serum Institute of India (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bavarian Nordic (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Viral Vaccine Sale, by Type, Disease, Side Effects, Patients and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Viral Vaccine (Value)
      • 7.2.1. Global Viral Vaccine by: Type (Value)
        • 7.2.1.1. Inactivated Vaccine
        • 7.2.1.2. Live-attenuated Vaccine
        • 7.2.1.3. Viral vector Vaccine
        • 7.2.1.4. Nucleic acid Vaccine
        • 7.2.1.5. Others
      • 7.2.2. Global Viral Vaccine by: Disease (Value)
        • 7.2.2.1. Pneumococcal Disease
        • 7.2.2.2. DTP
        • 7.2.2.3. Influenza
        • 7.2.2.4. HPV
        • 7.2.2.5. Meningococcal Disease
        • 7.2.2.6. Polio
        • 7.2.2.7. Rotavirus
        • 7.2.2.8. Hepatitis
        • 7.2.2.9. MMR
        • 7.2.2.10. Varicella
        • 7.2.2.11. Herpes zoster
        • 7.2.2.12. Other
      • 7.2.3. Global Viral Vaccine by: Side Effects (Value)
        • 7.2.3.1. Pain, swelling, or redness
        • 7.2.3.2. Mild fever
        • 7.2.3.3. Chills
        • 7.2.3.4. Feeling tired
        • 7.2.3.5. Headache
        • 7.2.3.6. Muscle and joint aches
      • 7.2.4. Global Viral Vaccine by: Patients (Value)
        • 7.2.4.1. Pediatric Patients
        • 7.2.4.2. Adult Patients
      • 7.2.5. Global Viral Vaccine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Viral Vaccine (Volume)
      • 7.3.1. Global Viral Vaccine by: Type (Volume)
        • 7.3.1.1. Inactivated Vaccine
        • 7.3.1.2. Live-attenuated Vaccine
        • 7.3.1.3. Viral vector Vaccine
        • 7.3.1.4. Nucleic acid Vaccine
        • 7.3.1.5. Others
      • 7.3.2. Global Viral Vaccine by: Disease (Volume)
        • 7.3.2.1. Pneumococcal Disease
        • 7.3.2.2. DTP
        • 7.3.2.3. Influenza
        • 7.3.2.4. HPV
        • 7.3.2.5. Meningococcal Disease
        • 7.3.2.6. Polio
        • 7.3.2.7. Rotavirus
        • 7.3.2.8. Hepatitis
        • 7.3.2.9. MMR
        • 7.3.2.10. Varicella
        • 7.3.2.11. Herpes zoster
        • 7.3.2.12. Other
      • 7.3.3. Global Viral Vaccine by: Side Effects (Volume)
        • 7.3.3.1. Pain, swelling, or redness
        • 7.3.3.2. Mild fever
        • 7.3.3.3. Chills
        • 7.3.3.4. Feeling tired
        • 7.3.3.5. Headache
        • 7.3.3.6. Muscle and joint aches
      • 7.3.4. Global Viral Vaccine by: Patients (Volume)
        • 7.3.4.1. Pediatric Patients
        • 7.3.4.2. Adult Patients
      • 7.3.5. Global Viral Vaccine Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Viral Vaccine (Price)
      • 7.4.1. Global Viral Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Viral Vaccine: by Type(USD Million)
  • Table 2. Viral Vaccine Inactivated Vaccine , by Region USD Million (2017-2022)
  • Table 3. Viral Vaccine Live-attenuated Vaccine , by Region USD Million (2017-2022)
  • Table 4. Viral Vaccine Viral vector Vaccine , by Region USD Million (2017-2022)
  • Table 5. Viral Vaccine Nucleic acid Vaccine , by Region USD Million (2017-2022)
  • Table 6. Viral Vaccine Others , by Region USD Million (2017-2022)
  • Table 7. Viral Vaccine: by Disease(USD Million)
  • Table 8. Viral Vaccine Pneumococcal Disease , by Region USD Million (2017-2022)
  • Table 9. Viral Vaccine DTP , by Region USD Million (2017-2022)
  • Table 10. Viral Vaccine Influenza , by Region USD Million (2017-2022)
  • Table 11. Viral Vaccine HPV , by Region USD Million (2017-2022)
  • Table 12. Viral Vaccine Meningococcal Disease , by Region USD Million (2017-2022)
  • Table 13. Viral Vaccine Polio , by Region USD Million (2017-2022)
  • Table 14. Viral Vaccine Rotavirus , by Region USD Million (2017-2022)
  • Table 15. Viral Vaccine Hepatitis , by Region USD Million (2017-2022)
  • Table 16. Viral Vaccine MMR , by Region USD Million (2017-2022)
  • Table 17. Viral Vaccine Varicella , by Region USD Million (2017-2022)
  • Table 18. Viral Vaccine Herpes zoster , by Region USD Million (2017-2022)
  • Table 19. Viral Vaccine Other , by Region USD Million (2017-2022)
  • Table 20. Viral Vaccine: by Side Effects(USD Million)
  • Table 21. Viral Vaccine Pain, swelling, or redness , by Region USD Million (2017-2022)
  • Table 22. Viral Vaccine Mild fever , by Region USD Million (2017-2022)
  • Table 23. Viral Vaccine Chills , by Region USD Million (2017-2022)
  • Table 24. Viral Vaccine Feeling tired , by Region USD Million (2017-2022)
  • Table 25. Viral Vaccine Headache , by Region USD Million (2017-2022)
  • Table 26. Viral Vaccine Muscle and joint aches , by Region USD Million (2017-2022)
  • Table 27. Viral Vaccine: by Patients(USD Million)
  • Table 28. Viral Vaccine Pediatric Patients , by Region USD Million (2017-2022)
  • Table 29. Viral Vaccine Adult Patients , by Region USD Million (2017-2022)
  • Table 30. South America Viral Vaccine, by Country USD Million (2017-2022)
  • Table 31. South America Viral Vaccine, by Type USD Million (2017-2022)
  • Table 32. South America Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 33. South America Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 34. South America Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 35. Brazil Viral Vaccine, by Type USD Million (2017-2022)
  • Table 36. Brazil Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 37. Brazil Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 38. Brazil Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 39. Argentina Viral Vaccine, by Type USD Million (2017-2022)
  • Table 40. Argentina Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 41. Argentina Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 42. Argentina Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 43. Rest of South America Viral Vaccine, by Type USD Million (2017-2022)
  • Table 44. Rest of South America Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 45. Rest of South America Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 46. Rest of South America Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 47. Asia Pacific Viral Vaccine, by Country USD Million (2017-2022)
  • Table 48. Asia Pacific Viral Vaccine, by Type USD Million (2017-2022)
  • Table 49. Asia Pacific Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 50. Asia Pacific Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 51. Asia Pacific Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 52. China Viral Vaccine, by Type USD Million (2017-2022)
  • Table 53. China Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 54. China Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 55. China Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 56. Japan Viral Vaccine, by Type USD Million (2017-2022)
  • Table 57. Japan Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 58. Japan Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 59. Japan Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 60. India Viral Vaccine, by Type USD Million (2017-2022)
  • Table 61. India Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 62. India Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 63. India Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 64. South Korea Viral Vaccine, by Type USD Million (2017-2022)
  • Table 65. South Korea Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 66. South Korea Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 67. South Korea Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 68. Taiwan Viral Vaccine, by Type USD Million (2017-2022)
  • Table 69. Taiwan Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 70. Taiwan Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 71. Taiwan Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 72. Australia Viral Vaccine, by Type USD Million (2017-2022)
  • Table 73. Australia Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 74. Australia Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 75. Australia Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 76. Rest of Asia-Pacific Viral Vaccine, by Type USD Million (2017-2022)
  • Table 77. Rest of Asia-Pacific Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 78. Rest of Asia-Pacific Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 79. Rest of Asia-Pacific Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 80. Europe Viral Vaccine, by Country USD Million (2017-2022)
  • Table 81. Europe Viral Vaccine, by Type USD Million (2017-2022)
  • Table 82. Europe Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 83. Europe Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 84. Europe Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 85. Germany Viral Vaccine, by Type USD Million (2017-2022)
  • Table 86. Germany Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 87. Germany Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 88. Germany Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 89. France Viral Vaccine, by Type USD Million (2017-2022)
  • Table 90. France Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 91. France Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 92. France Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 93. Italy Viral Vaccine, by Type USD Million (2017-2022)
  • Table 94. Italy Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 95. Italy Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 96. Italy Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 97. United Kingdom Viral Vaccine, by Type USD Million (2017-2022)
  • Table 98. United Kingdom Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 99. United Kingdom Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 100. United Kingdom Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 101. Netherlands Viral Vaccine, by Type USD Million (2017-2022)
  • Table 102. Netherlands Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 103. Netherlands Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 104. Netherlands Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 105. Rest of Europe Viral Vaccine, by Type USD Million (2017-2022)
  • Table 106. Rest of Europe Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 107. Rest of Europe Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 108. Rest of Europe Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 109. MEA Viral Vaccine, by Country USD Million (2017-2022)
  • Table 110. MEA Viral Vaccine, by Type USD Million (2017-2022)
  • Table 111. MEA Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 112. MEA Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 113. MEA Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 114. Middle East Viral Vaccine, by Type USD Million (2017-2022)
  • Table 115. Middle East Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 116. Middle East Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 117. Middle East Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 118. Africa Viral Vaccine, by Type USD Million (2017-2022)
  • Table 119. Africa Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 120. Africa Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 121. Africa Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 122. North America Viral Vaccine, by Country USD Million (2017-2022)
  • Table 123. North America Viral Vaccine, by Type USD Million (2017-2022)
  • Table 124. North America Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 125. North America Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 126. North America Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 127. United States Viral Vaccine, by Type USD Million (2017-2022)
  • Table 128. United States Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 129. United States Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 130. United States Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 131. Canada Viral Vaccine, by Type USD Million (2017-2022)
  • Table 132. Canada Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 133. Canada Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 134. Canada Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 135. Mexico Viral Vaccine, by Type USD Million (2017-2022)
  • Table 136. Mexico Viral Vaccine, by Disease USD Million (2017-2022)
  • Table 137. Mexico Viral Vaccine, by Side Effects USD Million (2017-2022)
  • Table 138. Mexico Viral Vaccine, by Patients USD Million (2017-2022)
  • Table 139. Viral Vaccine Sales: by Type(K Units)
  • Table 140. Viral Vaccine Sales Inactivated Vaccine , by Region K Units (2017-2022)
  • Table 141. Viral Vaccine Sales Live-attenuated Vaccine , by Region K Units (2017-2022)
  • Table 142. Viral Vaccine Sales Viral vector Vaccine , by Region K Units (2017-2022)
  • Table 143. Viral Vaccine Sales Nucleic acid Vaccine , by Region K Units (2017-2022)
  • Table 144. Viral Vaccine Sales Others , by Region K Units (2017-2022)
  • Table 145. Viral Vaccine Sales: by Disease(K Units)
  • Table 146. Viral Vaccine Sales Pneumococcal Disease , by Region K Units (2017-2022)
  • Table 147. Viral Vaccine Sales DTP , by Region K Units (2017-2022)
  • Table 148. Viral Vaccine Sales Influenza , by Region K Units (2017-2022)
  • Table 149. Viral Vaccine Sales HPV , by Region K Units (2017-2022)
  • Table 150. Viral Vaccine Sales Meningococcal Disease , by Region K Units (2017-2022)
  • Table 151. Viral Vaccine Sales Polio , by Region K Units (2017-2022)
  • Table 152. Viral Vaccine Sales Rotavirus , by Region K Units (2017-2022)
  • Table 153. Viral Vaccine Sales Hepatitis , by Region K Units (2017-2022)
  • Table 154. Viral Vaccine Sales MMR , by Region K Units (2017-2022)
  • Table 155. Viral Vaccine Sales Varicella , by Region K Units (2017-2022)
  • Table 156. Viral Vaccine Sales Herpes zoster , by Region K Units (2017-2022)
  • Table 157. Viral Vaccine Sales Other , by Region K Units (2017-2022)
  • Table 158. Viral Vaccine Sales: by Side Effects(K Units)
  • Table 159. Viral Vaccine Sales Pain, swelling, or redness , by Region K Units (2017-2022)
  • Table 160. Viral Vaccine Sales Mild fever , by Region K Units (2017-2022)
  • Table 161. Viral Vaccine Sales Chills , by Region K Units (2017-2022)
  • Table 162. Viral Vaccine Sales Feeling tired , by Region K Units (2017-2022)
  • Table 163. Viral Vaccine Sales Headache , by Region K Units (2017-2022)
  • Table 164. Viral Vaccine Sales Muscle and joint aches , by Region K Units (2017-2022)
  • Table 165. Viral Vaccine Sales: by Patients(K Units)
  • Table 166. Viral Vaccine Sales Pediatric Patients , by Region K Units (2017-2022)
  • Table 167. Viral Vaccine Sales Adult Patients , by Region K Units (2017-2022)
  • Table 168. South America Viral Vaccine Sales, by Country K Units (2017-2022)
  • Table 169. South America Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 170. South America Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 171. South America Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 172. South America Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 173. Brazil Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 174. Brazil Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 175. Brazil Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 176. Brazil Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 177. Argentina Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 178. Argentina Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 179. Argentina Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 180. Argentina Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 181. Rest of South America Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 182. Rest of South America Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 183. Rest of South America Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 184. Rest of South America Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 185. Asia Pacific Viral Vaccine Sales, by Country K Units (2017-2022)
  • Table 186. Asia Pacific Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 187. Asia Pacific Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 188. Asia Pacific Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 189. Asia Pacific Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 190. China Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 191. China Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 192. China Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 193. China Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 194. Japan Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 195. Japan Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 196. Japan Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 197. Japan Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 198. India Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 199. India Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 200. India Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 201. India Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 202. South Korea Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 203. South Korea Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 204. South Korea Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 205. South Korea Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 206. Taiwan Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 207. Taiwan Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 208. Taiwan Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 209. Taiwan Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 210. Australia Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 211. Australia Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 212. Australia Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 213. Australia Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 214. Rest of Asia-Pacific Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 215. Rest of Asia-Pacific Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 216. Rest of Asia-Pacific Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 217. Rest of Asia-Pacific Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 218. Europe Viral Vaccine Sales, by Country K Units (2017-2022)
  • Table 219. Europe Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 220. Europe Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 221. Europe Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 222. Europe Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 223. Germany Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 224. Germany Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 225. Germany Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 226. Germany Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 227. France Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 228. France Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 229. France Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 230. France Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 231. Italy Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 232. Italy Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 233. Italy Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 234. Italy Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 235. United Kingdom Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 236. United Kingdom Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 237. United Kingdom Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 238. United Kingdom Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 239. Netherlands Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 240. Netherlands Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 241. Netherlands Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 242. Netherlands Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 243. Rest of Europe Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 244. Rest of Europe Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 245. Rest of Europe Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 246. Rest of Europe Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 247. MEA Viral Vaccine Sales, by Country K Units (2017-2022)
  • Table 248. MEA Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 249. MEA Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 250. MEA Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 251. MEA Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 252. Middle East Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 253. Middle East Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 254. Middle East Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 255. Middle East Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 256. Africa Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 257. Africa Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 258. Africa Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 259. Africa Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 260. North America Viral Vaccine Sales, by Country K Units (2017-2022)
  • Table 261. North America Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 262. North America Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 263. North America Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 264. North America Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 265. United States Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 266. United States Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 267. United States Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 268. United States Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 269. Canada Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 270. Canada Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 271. Canada Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 272. Canada Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 273. Mexico Viral Vaccine Sales, by Type K Units (2017-2022)
  • Table 274. Mexico Viral Vaccine Sales, by Disease K Units (2017-2022)
  • Table 275. Mexico Viral Vaccine Sales, by Side Effects K Units (2017-2022)
  • Table 276. Mexico Viral Vaccine Sales, by Patients K Units (2017-2022)
  • Table 277. Viral Vaccine: by Type(USD/Units)
  • Table 278. Company Basic Information, Sales Area and Its Competitors
  • Table 279. Company Basic Information, Sales Area and Its Competitors
  • Table 280. Company Basic Information, Sales Area and Its Competitors
  • Table 281. Company Basic Information, Sales Area and Its Competitors
  • Table 282. Company Basic Information, Sales Area and Its Competitors
  • Table 283. Company Basic Information, Sales Area and Its Competitors
  • Table 284. Company Basic Information, Sales Area and Its Competitors
  • Table 285. Company Basic Information, Sales Area and Its Competitors
  • Table 286. Company Basic Information, Sales Area and Its Competitors
  • Table 287. Company Basic Information, Sales Area and Its Competitors
  • Table 288. Viral Vaccine: by Type(USD Million)
  • Table 289. Viral Vaccine Inactivated Vaccine , by Region USD Million (2023-2028)
  • Table 290. Viral Vaccine Live-attenuated Vaccine , by Region USD Million (2023-2028)
  • Table 291. Viral Vaccine Viral vector Vaccine , by Region USD Million (2023-2028)
  • Table 292. Viral Vaccine Nucleic acid Vaccine , by Region USD Million (2023-2028)
  • Table 293. Viral Vaccine Others , by Region USD Million (2023-2028)
  • Table 294. Viral Vaccine: by Disease(USD Million)
  • Table 295. Viral Vaccine Pneumococcal Disease , by Region USD Million (2023-2028)
  • Table 296. Viral Vaccine DTP , by Region USD Million (2023-2028)
  • Table 297. Viral Vaccine Influenza , by Region USD Million (2023-2028)
  • Table 298. Viral Vaccine HPV , by Region USD Million (2023-2028)
  • Table 299. Viral Vaccine Meningococcal Disease , by Region USD Million (2023-2028)
  • Table 300. Viral Vaccine Polio , by Region USD Million (2023-2028)
  • Table 301. Viral Vaccine Rotavirus , by Region USD Million (2023-2028)
  • Table 302. Viral Vaccine Hepatitis , by Region USD Million (2023-2028)
  • Table 303. Viral Vaccine MMR , by Region USD Million (2023-2028)
  • Table 304. Viral Vaccine Varicella , by Region USD Million (2023-2028)
  • Table 305. Viral Vaccine Herpes zoster , by Region USD Million (2023-2028)
  • Table 306. Viral Vaccine Other , by Region USD Million (2023-2028)
  • Table 307. Viral Vaccine: by Side Effects(USD Million)
  • Table 308. Viral Vaccine Pain, swelling, or redness , by Region USD Million (2023-2028)
  • Table 309. Viral Vaccine Mild fever , by Region USD Million (2023-2028)
  • Table 310. Viral Vaccine Chills , by Region USD Million (2023-2028)
  • Table 311. Viral Vaccine Feeling tired , by Region USD Million (2023-2028)
  • Table 312. Viral Vaccine Headache , by Region USD Million (2023-2028)
  • Table 313. Viral Vaccine Muscle and joint aches , by Region USD Million (2023-2028)
  • Table 314. Viral Vaccine: by Patients(USD Million)
  • Table 315. Viral Vaccine Pediatric Patients , by Region USD Million (2023-2028)
  • Table 316. Viral Vaccine Adult Patients , by Region USD Million (2023-2028)
  • Table 317. South America Viral Vaccine, by Country USD Million (2023-2028)
  • Table 318. South America Viral Vaccine, by Type USD Million (2023-2028)
  • Table 319. South America Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 320. South America Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 321. South America Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 322. Brazil Viral Vaccine, by Type USD Million (2023-2028)
  • Table 323. Brazil Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 324. Brazil Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 325. Brazil Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 326. Argentina Viral Vaccine, by Type USD Million (2023-2028)
  • Table 327. Argentina Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 328. Argentina Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 329. Argentina Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 330. Rest of South America Viral Vaccine, by Type USD Million (2023-2028)
  • Table 331. Rest of South America Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 332. Rest of South America Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 333. Rest of South America Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 334. Asia Pacific Viral Vaccine, by Country USD Million (2023-2028)
  • Table 335. Asia Pacific Viral Vaccine, by Type USD Million (2023-2028)
  • Table 336. Asia Pacific Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 337. Asia Pacific Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 338. Asia Pacific Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 339. China Viral Vaccine, by Type USD Million (2023-2028)
  • Table 340. China Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 341. China Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 342. China Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 343. Japan Viral Vaccine, by Type USD Million (2023-2028)
  • Table 344. Japan Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 345. Japan Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 346. Japan Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 347. India Viral Vaccine, by Type USD Million (2023-2028)
  • Table 348. India Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 349. India Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 350. India Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 351. South Korea Viral Vaccine, by Type USD Million (2023-2028)
  • Table 352. South Korea Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 353. South Korea Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 354. South Korea Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 355. Taiwan Viral Vaccine, by Type USD Million (2023-2028)
  • Table 356. Taiwan Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 357. Taiwan Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 358. Taiwan Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 359. Australia Viral Vaccine, by Type USD Million (2023-2028)
  • Table 360. Australia Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 361. Australia Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 362. Australia Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 363. Rest of Asia-Pacific Viral Vaccine, by Type USD Million (2023-2028)
  • Table 364. Rest of Asia-Pacific Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 365. Rest of Asia-Pacific Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 366. Rest of Asia-Pacific Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 367. Europe Viral Vaccine, by Country USD Million (2023-2028)
  • Table 368. Europe Viral Vaccine, by Type USD Million (2023-2028)
  • Table 369. Europe Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 370. Europe Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 371. Europe Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 372. Germany Viral Vaccine, by Type USD Million (2023-2028)
  • Table 373. Germany Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 374. Germany Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 375. Germany Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 376. France Viral Vaccine, by Type USD Million (2023-2028)
  • Table 377. France Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 378. France Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 379. France Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 380. Italy Viral Vaccine, by Type USD Million (2023-2028)
  • Table 381. Italy Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 382. Italy Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 383. Italy Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 384. United Kingdom Viral Vaccine, by Type USD Million (2023-2028)
  • Table 385. United Kingdom Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 386. United Kingdom Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 387. United Kingdom Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 388. Netherlands Viral Vaccine, by Type USD Million (2023-2028)
  • Table 389. Netherlands Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 390. Netherlands Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 391. Netherlands Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 392. Rest of Europe Viral Vaccine, by Type USD Million (2023-2028)
  • Table 393. Rest of Europe Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 394. Rest of Europe Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 395. Rest of Europe Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 396. MEA Viral Vaccine, by Country USD Million (2023-2028)
  • Table 397. MEA Viral Vaccine, by Type USD Million (2023-2028)
  • Table 398. MEA Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 399. MEA Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 400. MEA Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 401. Middle East Viral Vaccine, by Type USD Million (2023-2028)
  • Table 402. Middle East Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 403. Middle East Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 404. Middle East Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 405. Africa Viral Vaccine, by Type USD Million (2023-2028)
  • Table 406. Africa Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 407. Africa Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 408. Africa Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 409. North America Viral Vaccine, by Country USD Million (2023-2028)
  • Table 410. North America Viral Vaccine, by Type USD Million (2023-2028)
  • Table 411. North America Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 412. North America Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 413. North America Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 414. United States Viral Vaccine, by Type USD Million (2023-2028)
  • Table 415. United States Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 416. United States Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 417. United States Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 418. Canada Viral Vaccine, by Type USD Million (2023-2028)
  • Table 419. Canada Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 420. Canada Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 421. Canada Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 422. Mexico Viral Vaccine, by Type USD Million (2023-2028)
  • Table 423. Mexico Viral Vaccine, by Disease USD Million (2023-2028)
  • Table 424. Mexico Viral Vaccine, by Side Effects USD Million (2023-2028)
  • Table 425. Mexico Viral Vaccine, by Patients USD Million (2023-2028)
  • Table 426. Viral Vaccine Sales: by Type(K Units)
  • Table 427. Viral Vaccine Sales Inactivated Vaccine , by Region K Units (2023-2028)
  • Table 428. Viral Vaccine Sales Live-attenuated Vaccine , by Region K Units (2023-2028)
  • Table 429. Viral Vaccine Sales Viral vector Vaccine , by Region K Units (2023-2028)
  • Table 430. Viral Vaccine Sales Nucleic acid Vaccine , by Region K Units (2023-2028)
  • Table 431. Viral Vaccine Sales Others , by Region K Units (2023-2028)
  • Table 432. Viral Vaccine Sales: by Disease(K Units)
  • Table 433. Viral Vaccine Sales Pneumococcal Disease , by Region K Units (2023-2028)
  • Table 434. Viral Vaccine Sales DTP , by Region K Units (2023-2028)
  • Table 435. Viral Vaccine Sales Influenza , by Region K Units (2023-2028)
  • Table 436. Viral Vaccine Sales HPV , by Region K Units (2023-2028)
  • Table 437. Viral Vaccine Sales Meningococcal Disease , by Region K Units (2023-2028)
  • Table 438. Viral Vaccine Sales Polio , by Region K Units (2023-2028)
  • Table 439. Viral Vaccine Sales Rotavirus , by Region K Units (2023-2028)
  • Table 440. Viral Vaccine Sales Hepatitis , by Region K Units (2023-2028)
  • Table 441. Viral Vaccine Sales MMR , by Region K Units (2023-2028)
  • Table 442. Viral Vaccine Sales Varicella , by Region K Units (2023-2028)
  • Table 443. Viral Vaccine Sales Herpes zoster , by Region K Units (2023-2028)
  • Table 444. Viral Vaccine Sales Other , by Region K Units (2023-2028)
  • Table 445. Viral Vaccine Sales: by Side Effects(K Units)
  • Table 446. Viral Vaccine Sales Pain, swelling, or redness , by Region K Units (2023-2028)
  • Table 447. Viral Vaccine Sales Mild fever , by Region K Units (2023-2028)
  • Table 448. Viral Vaccine Sales Chills , by Region K Units (2023-2028)
  • Table 449. Viral Vaccine Sales Feeling tired , by Region K Units (2023-2028)
  • Table 450. Viral Vaccine Sales Headache , by Region K Units (2023-2028)
  • Table 451. Viral Vaccine Sales Muscle and joint aches , by Region K Units (2023-2028)
  • Table 452. Viral Vaccine Sales: by Patients(K Units)
  • Table 453. Viral Vaccine Sales Pediatric Patients , by Region K Units (2023-2028)
  • Table 454. Viral Vaccine Sales Adult Patients , by Region K Units (2023-2028)
  • Table 455. South America Viral Vaccine Sales, by Country K Units (2023-2028)
  • Table 456. South America Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 457. South America Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 458. South America Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 459. South America Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 460. Brazil Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 461. Brazil Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 462. Brazil Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 463. Brazil Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 464. Argentina Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 465. Argentina Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 466. Argentina Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 467. Argentina Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 468. Rest of South America Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 469. Rest of South America Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 470. Rest of South America Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 471. Rest of South America Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 472. Asia Pacific Viral Vaccine Sales, by Country K Units (2023-2028)
  • Table 473. Asia Pacific Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 474. Asia Pacific Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 475. Asia Pacific Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 476. Asia Pacific Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 477. China Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 478. China Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 479. China Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 480. China Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 481. Japan Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 482. Japan Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 483. Japan Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 484. Japan Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 485. India Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 486. India Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 487. India Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 488. India Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 489. South Korea Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 490. South Korea Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 491. South Korea Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 492. South Korea Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 493. Taiwan Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 494. Taiwan Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 495. Taiwan Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 496. Taiwan Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 497. Australia Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 498. Australia Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 499. Australia Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 500. Australia Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 501. Rest of Asia-Pacific Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 502. Rest of Asia-Pacific Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 503. Rest of Asia-Pacific Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 504. Rest of Asia-Pacific Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 505. Europe Viral Vaccine Sales, by Country K Units (2023-2028)
  • Table 506. Europe Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 507. Europe Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 508. Europe Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 509. Europe Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 510. Germany Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 511. Germany Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 512. Germany Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 513. Germany Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 514. France Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 515. France Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 516. France Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 517. France Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 518. Italy Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 519. Italy Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 520. Italy Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 521. Italy Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 522. United Kingdom Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 523. United Kingdom Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 524. United Kingdom Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 525. United Kingdom Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 526. Netherlands Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 527. Netherlands Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 528. Netherlands Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 529. Netherlands Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 530. Rest of Europe Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 531. Rest of Europe Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 532. Rest of Europe Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 533. Rest of Europe Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 534. MEA Viral Vaccine Sales, by Country K Units (2023-2028)
  • Table 535. MEA Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 536. MEA Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 537. MEA Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 538. MEA Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 539. Middle East Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 540. Middle East Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 541. Middle East Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 542. Middle East Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 543. Africa Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 544. Africa Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 545. Africa Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 546. Africa Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 547. North America Viral Vaccine Sales, by Country K Units (2023-2028)
  • Table 548. North America Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 549. North America Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 550. North America Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 551. North America Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 552. United States Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 553. United States Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 554. United States Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 555. United States Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 556. Canada Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 557. Canada Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 558. Canada Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 559. Canada Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 560. Mexico Viral Vaccine Sales, by Type K Units (2023-2028)
  • Table 561. Mexico Viral Vaccine Sales, by Disease K Units (2023-2028)
  • Table 562. Mexico Viral Vaccine Sales, by Side Effects K Units (2023-2028)
  • Table 563. Mexico Viral Vaccine Sales, by Patients K Units (2023-2028)
  • Table 564. Viral Vaccine: by Type(USD/Units)
  • Table 565. Research Programs/Design for This Report
  • Table 566. Key Data Information from Secondary Sources
  • Table 567. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Viral Vaccine: by Type USD Million (2017-2022)
  • Figure 5. Global Viral Vaccine: by Disease USD Million (2017-2022)
  • Figure 6. Global Viral Vaccine: by Side Effects USD Million (2017-2022)
  • Figure 7. Global Viral Vaccine: by Patients USD Million (2017-2022)
  • Figure 8. South America Viral Vaccine Share (%), by Country
  • Figure 9. Asia Pacific Viral Vaccine Share (%), by Country
  • Figure 10. Europe Viral Vaccine Share (%), by Country
  • Figure 11. MEA Viral Vaccine Share (%), by Country
  • Figure 12. North America Viral Vaccine Share (%), by Country
  • Figure 13. Global Viral Vaccine: by Type K Units (2017-2022)
  • Figure 14. Global Viral Vaccine: by Disease K Units (2017-2022)
  • Figure 15. Global Viral Vaccine: by Side Effects K Units (2017-2022)
  • Figure 16. Global Viral Vaccine: by Patients K Units (2017-2022)
  • Figure 17. South America Viral Vaccine Share (%), by Country
  • Figure 18. Asia Pacific Viral Vaccine Share (%), by Country
  • Figure 19. Europe Viral Vaccine Share (%), by Country
  • Figure 20. MEA Viral Vaccine Share (%), by Country
  • Figure 21. North America Viral Vaccine Share (%), by Country
  • Figure 22. Global Viral Vaccine: by Type USD/Units (2017-2022)
  • Figure 23. Global Viral Vaccine share by Players 2022 (%)
  • Figure 24. Global Viral Vaccine share by Players (Top 3) 2022(%)
  • Figure 25. Global Viral Vaccine share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 33. Sanofi Pasteur SA (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi Pasteur SA (France) Revenue: by Geography 2022
  • Figure 35. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 36. CSL Limited (Australia) Revenue: by Geography 2022
  • Figure 37. Emergent BioSolutions, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Emergent BioSolutions, Inc. (United States) Revenue: by Geography 2022
  • Figure 39. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 40. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 41. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 42. Serum Institute of India (India) Revenue: by Geography 2022
  • Figure 43. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 45. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 46. Bavarian Nordic (Denmark) Revenue: by Geography 2022
  • Figure 47. Global Viral Vaccine: by Type USD Million (2023-2028)
  • Figure 48. Global Viral Vaccine: by Disease USD Million (2023-2028)
  • Figure 49. Global Viral Vaccine: by Side Effects USD Million (2023-2028)
  • Figure 50. Global Viral Vaccine: by Patients USD Million (2023-2028)
  • Figure 51. South America Viral Vaccine Share (%), by Country
  • Figure 52. Asia Pacific Viral Vaccine Share (%), by Country
  • Figure 53. Europe Viral Vaccine Share (%), by Country
  • Figure 54. MEA Viral Vaccine Share (%), by Country
  • Figure 55. North America Viral Vaccine Share (%), by Country
  • Figure 56. Global Viral Vaccine: by Type K Units (2023-2028)
  • Figure 57. Global Viral Vaccine: by Disease K Units (2023-2028)
  • Figure 58. Global Viral Vaccine: by Side Effects K Units (2023-2028)
  • Figure 59. Global Viral Vaccine: by Patients K Units (2023-2028)
  • Figure 60. South America Viral Vaccine Share (%), by Country
  • Figure 61. Asia Pacific Viral Vaccine Share (%), by Country
  • Figure 62. Europe Viral Vaccine Share (%), by Country
  • Figure 63. MEA Viral Vaccine Share (%), by Country
  • Figure 64. North America Viral Vaccine Share (%), by Country
  • Figure 65. Global Viral Vaccine: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc. (United Kingdom)
  • Pfizer, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Sanofi Pasteur SA (France)
  • CSL Limited (Australia)
  • Emergent BioSolutions, Inc. (United States)
  • Johnson & Johnson (United States)
  • Serum Institute of India (India)
  • AstraZeneca (United Kingdom)
  • Bavarian Nordic (Denmark)
Additional players considered in the study are as follows:
Mitsubishi Tanabe Pharma Corporation (Japan) , Daiichi Sankyo Company, Limited (Japan)
Select User Access Type

Key Highlights of Report


Mar 2023 170 Pages 77 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Viral Vaccine Quantitative research analysis
Global Viral Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Viral Vaccine market are GlaxoSmithKline plc. (United Kingdom), Pfizer, Inc. (United States), Merck & Co., Inc. (United States), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (United States), Johnson & Johnson (United States), Serum Institute of India (India), AstraZeneca (United Kingdom) and Bavarian Nordic (Denmark), to name a few.
"Introduction to new vaccines and technology" is seen as one of major influencing trends for Viral Vaccine Market during projected period 2022-2028.
Inactivated Vaccine segment in Global market to hold robust market share owing to "Rising number of companies to enhance R&D ".

Know More About Global Viral Vaccine Report?

Have a Query? Click Here

Other Related Reports

Metformin Hydrochloride API Comprehensive Study by Type (Metformin HCL, Metformin DC, Others), Sales Channels (Direct Sales, In-Direct Sales), Grade (IP, EP, BP, USP) Players and Region - Global Mark...
$ 3500
Kidney Renal Cancer Drugs Comprehensive Study by Type (Anti-angiogenesis therapy, Tyrosine kinase inhibitors (TKIs), MTOR inhibitors), Application (Clear cell renal cell carcinomas (ccRCC), Papillary...
$ 3650
Medical Suppositories Comprehensive Study by Type (Rectal Suppositories, Vaginal Suppositories, Urethral Suppositories), Application (Pediatrics, Geriatrics, Gynaecology), End Users (Hospitals, Clini...
$ 3450
Pharmaceutical Contract Sales Outsourcing Comprehensive Study by Type (Pharmaceutical Equipment’s, Finished Drugs), Services (Clinical Trials, Biomedical Research), End Users (Healthcare Organization...
$ 3450
Specialty Generic Drug Comprehensive Study by Type (Oral, Parenteral, Topical, Injectable, Others.), Application (Cancer, Rheumatoid Arthritis, Hemophilia, H.I.V. Psoriasis, Inflammatory Bowel Diseas...
$ 3450
Codeine Drug Comprehensive Study by Type (Tablets, Syrup), Sales Channels (Direct Sales, In-Direct Sales), End Users (Hospitals, Clinics), Treatment (Pain, Cough, Diarrhea, Others), Form (Tablets, Sy...
$ 3500